Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL145650 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL3406205 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL29360959 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13764364 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13785162 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL34339 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1649712 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL4740285 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1720497 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL2755938 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5394 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-224290539-U | Perovskite solar cell module | Liyuan New Energy Technology (Wuxi) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4724119-A2 | LIVER SUPPORT SYSTEMS AND METHODS OF USE | Kanto Biomedicines, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12565680-B2 | Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy | THE METHODIST HOSPITAL SYSTEM (US) | 2026-03-03 | — | — | US | claimed |
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025235516-A1 | DEVELOPMENT OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS AS ANTI-CANCER REAGENTS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| WO-2025106897-A1 | METHODS AND COMPOSITIONS FOR CREATING INDUCED PLURIPOTENT STEM CELLS | COLOSSAL BIOSCIENCES INC. (US) | 2025-05-22 | — | — | WO | claimed |
| CN-119968006-A | Perovskite battery component and preparation method thereof | 深圳市光因科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| EP-0635508-A1 | TETRAHYDROPYRIDINE DERIVATIVE HAVING SUBSTITUENTS ON THREE RINGS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-01-25 | — | — | EP | claimed |
| US-5340838-A | Administering serotonin agonist to mammals | ELI LILLY AND COMPANY (US) | 1994-08-23 | — | — | US | claimed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| US-4977145-A | ADMINISTERING ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| EP-0035597-B1 | PHARMACEUTICAL PREPARATIONS | Röhm Pharma GmbH (DE) | 1984-08-01 | — | — | EP | claimed |
| US-4331687-A | /+/TRANS-2-PHENYLCYCLOPROPYLAMINE; ANTIDEPRESSANTS | ROHM PHARMA GMBH (DE) | 1982-05-25 | — | — | US | claimed |
| EP-0035597-A2 | Pharmaceutical preparations | Röhm Pharma GmbH (DE) | 1981-09-16 | — | — | EP | claimed |
| US-3961073-A | 2-PHENYL-CYCLOPROPYLAMINE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-06-01 | — | — | US | claimed |